vs
Side-by-side financial comparison of Fortive (FTV) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Fortive is the larger business by last-quarter revenue ($1.1B vs $346.4M, roughly 3.1× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 12.8%, a 15.3% gap on every dollar of revenue. On growth, Fortive posted the faster year-over-year revenue change (7.7% vs 4.8%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -17.0%).
Fortive Corporation is an American industrial technology conglomerate company headquartered in Everett, Washington. The company specializes in providing essential technologies for connected workflow solutions; designing, developing, manufacturing and distributing professional and engineered products, software and services. Their products and services are split into three strategic segments; Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. As of Decem...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
FTV vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $346.4M |
| Net Profit | $136.4M | $97.3M |
| Gross Margin | 63.2% | 57.2% |
| Operating Margin | 17.9% | 36.1% |
| Net Margin | 12.8% | 28.1% |
| Revenue YoY | 7.7% | 4.8% |
| Net Profit YoY | 21.1% | — |
| EPS (diluted) | $0.44 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.1B | $346.4M | ||
| Q4 25 | $1.1B | $339.0M | ||
| Q3 25 | $1.0B | $327.3M | ||
| Q2 25 | $1.5B | $321.4M | ||
| Q1 25 | $1.5B | $330.6M | ||
| Q4 24 | $1.6B | $348.5M | ||
| Q3 24 | $1.5B | $345.5M | ||
| Q2 24 | $1.6B | $336.2M |
| Q1 26 | $136.4M | $97.3M | ||
| Q4 25 | $185.7M | $44.7M | ||
| Q3 25 | $55.0M | $38.7M | ||
| Q2 25 | $166.6M | $34.0M | ||
| Q1 25 | $171.9M | $58.0M | ||
| Q4 24 | $208.8M | $37.5M | ||
| Q3 24 | $221.6M | $33.8M | ||
| Q2 24 | $195.1M | $38.4M |
| Q1 26 | 63.2% | 57.2% | ||
| Q4 25 | 63.2% | 59.7% | ||
| Q3 25 | 63.2% | 59.5% | ||
| Q2 25 | 59.0% | 59.8% | ||
| Q1 25 | 59.8% | 58.4% | ||
| Q4 24 | 60.3% | 55.5% | ||
| Q3 24 | 60.0% | 54.2% | ||
| Q2 24 | 59.8% | 52.0% |
| Q1 26 | 17.9% | 36.1% | ||
| Q4 25 | 20.1% | 19.9% | ||
| Q3 25 | 15.5% | 17.9% | ||
| Q2 25 | 14.6% | 16.8% | ||
| Q1 25 | 15.8% | 21.6% | ||
| Q4 24 | 19.0% | 16.9% | ||
| Q3 24 | 19.3% | 15.0% | ||
| Q2 24 | 19.4% | 11.8% |
| Q1 26 | 12.8% | 28.1% | ||
| Q4 25 | 16.5% | 13.2% | ||
| Q3 25 | 5.4% | 11.8% | ||
| Q2 25 | 11.0% | 10.6% | ||
| Q1 25 | 11.7% | 17.5% | ||
| Q4 24 | 12.9% | 10.8% | ||
| Q3 24 | 14.4% | 9.8% | ||
| Q2 24 | 12.6% | 11.4% |
| Q1 26 | $0.44 | — | ||
| Q4 25 | $0.60 | $0.95 | ||
| Q3 25 | $0.16 | $0.81 | ||
| Q2 25 | $0.49 | $0.70 | ||
| Q1 25 | $0.50 | $1.17 | ||
| Q4 24 | $0.60 | $0.74 | ||
| Q3 24 | $0.63 | $0.66 | ||
| Q2 24 | $0.55 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $356.1M | $245.4M |
| Total DebtLower is stronger | $3.5B | $1.2B |
| Stockholders' EquityBook value | $6.1B | $796.3M |
| Total Assets | $11.6B | $2.4B |
| Debt / EquityLower = less leverage | 0.57× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $356.1M | $245.4M | ||
| Q4 25 | $375.5M | $363.4M | ||
| Q3 25 | $430.8M | $296.4M | ||
| Q2 25 | $1.8B | $292.9M | ||
| Q1 25 | $892.1M | $306.8M | ||
| Q4 24 | $813.3M | $320.8M | ||
| Q3 24 | $811.3M | $299.3M | ||
| Q2 24 | $644.1M | $344.4M |
| Q1 26 | $3.5B | $1.2B | ||
| Q4 25 | $3.2B | $1.2B | ||
| Q3 25 | $3.3B | $1.2B | ||
| Q2 25 | $4.8B | $1.2B | ||
| Q1 25 | $3.9B | $1.2B | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.9B | — | ||
| Q2 24 | $3.8B | — |
| Q1 26 | $6.1B | $796.3M | ||
| Q4 25 | $6.5B | $911.5M | ||
| Q3 25 | $6.5B | $849.2M | ||
| Q2 25 | $10.4B | $882.3M | ||
| Q1 25 | $10.2B | $820.8M | ||
| Q4 24 | $10.2B | $906.9M | ||
| Q3 24 | $10.6B | $878.9M | ||
| Q2 24 | $10.5B | $905.4M |
| Q1 26 | $11.6B | $2.4B | ||
| Q4 25 | $11.7B | $2.5B | ||
| Q3 25 | $11.9B | $2.4B | ||
| Q2 25 | $18.2B | $2.5B | ||
| Q1 25 | $17.1B | $2.5B | ||
| Q4 24 | $17.0B | $2.5B | ||
| Q3 24 | $17.5B | $2.5B | ||
| Q2 24 | $17.3B | $2.5B |
| Q1 26 | 0.57× | 1.53× | ||
| Q4 25 | 0.50× | 1.34× | ||
| Q3 25 | 0.51× | 1.44× | ||
| Q2 25 | 0.46× | 1.39× | ||
| Q1 25 | 0.38× | 1.49× | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $234.8M | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | 2.5% | 9.5% |
| Cash ConversionOCF / Net Profit | 1.72× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $234.8M | $293.2M | ||
| Q4 25 | $1.1B | $93.6M | ||
| Q3 25 | $164.4M | $111.3M | ||
| Q2 25 | $311.2M | $17.4M | ||
| Q1 25 | $241.7M | $116.6M | ||
| Q4 24 | $502.2M | $43.8M | ||
| Q3 24 | $459.0M | $48.8M | ||
| Q2 24 | $308.9M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $313.8M | $87.2M | ||
| Q3 25 | $153.1M | $106.3M | ||
| Q2 25 | $274.5M | $13.6M | ||
| Q1 25 | $215.0M | $100.9M | ||
| Q4 24 | $465.2M | $35.2M | ||
| Q3 24 | $431.2M | $39.4M | ||
| Q2 24 | $279.7M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 28.0% | 25.7% | ||
| Q3 25 | 14.9% | 32.5% | ||
| Q2 25 | 18.1% | 4.2% | ||
| Q1 25 | 14.6% | 30.5% | ||
| Q4 24 | 28.7% | 10.1% | ||
| Q3 24 | 28.1% | 11.4% | ||
| Q2 24 | 18.0% | -9.8% |
| Q1 26 | 2.5% | 9.5% | ||
| Q4 25 | 2.7% | 1.9% | ||
| Q3 25 | 1.1% | 1.5% | ||
| Q2 25 | 2.4% | 1.2% | ||
| Q1 25 | 1.8% | 4.7% | ||
| Q4 24 | 2.3% | 2.5% | ||
| Q3 24 | 1.8% | 2.7% | ||
| Q2 24 | 1.9% | 1.7% |
| Q1 26 | 1.72× | 3.01× | ||
| Q4 25 | 5.83× | 2.09× | ||
| Q3 25 | 2.99× | 2.88× | ||
| Q2 25 | 1.87× | 0.51× | ||
| Q1 25 | 1.41× | 2.01× | ||
| Q4 24 | 2.41× | 1.17× | ||
| Q3 24 | 2.07× | 1.44× | ||
| Q2 24 | 1.58× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FTV
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
